3'-(1-hydroxy-1-methyl-ethyl)-[1,1']bi[tricyclodecyl]-3-carboxylic acid | 1206697-42-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3'-(1-hydroxy-1-methyl-ethyl)-[1,1']bi[tricyclodecyl]-3-carboxylic acid
• 英文别名: 3-[3-(2-Hydroxypropan-2-yl)-1-adamantyl]adamantane-1-carboxylic acid
• CAS: 1206697-42-8
• 化学式: C₂₄H₃₆O₃
• 分子量: 372.548
• InChiKey: USQDTZXSUZDYRQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  [1,1']bi[tricyclodecyl]-3,3'-dicarboxylic acid 3'-methyl ester 、 甲基氯化镁 在 磷酸 、 水 作用下， 以 四氢呋喃 为溶剂， 以62%的产率得到3'-(1-hydroxy-1-methyl-ethyl)-[1,1']bi[tricyclodecyl]-3-carboxylic acid
  参考文献：
  名称：

  [EN] 1,1'-DIADAMANTYL CARBOXYLIC ACIDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE
  [FR] ACIDES 1,1'-DIADAMANTYL CARBOXYLIQUES, MÉDICAMENTS CONTENANT DE TELS COMPOSÉS ET APPLICATION ASSOCIÉE

  摘要：

  本发明涉及由式（I）定义的化合物，其中基团R如权利要求1中所定义，具有有价值的药理活性。特别是这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，如代谢性疾病。

  公开号：

  WO2010010174A1

文献信息

• HNF4-alpha ANTAGONIST AND USE THEREOF
  申请人：NATIONAL CANCER CENTER

  公开号：US20160193238A1

  公开（公告）日：2016-07-07

  Provided is a hepatocyte nuclear factor 4 alpha (HNF4-α) antagonist and a use thereof. The HNF4-α antagonist selected in the present invention was confirmed to specifically bind to the ligand binding domain of HNF4-α, thereby inhibiting the activity of HNF4-α. The HNF4-α antagonist of the present invention can significantly reduce the expression of Wnt5a in a specific manner compared to that of the conventional known HNF4-α antagonists, and can also inhibit the growth of gastric cancer cells. Therefore, the HNF4-α antagonist of the present invention can not only be used as a pharmaceutical composition or a health functional food for preventing and treating cancer but can also be applied to a composition for treating or preventing diseases occurring due to the overexpression of HNF4-α.

  提供了一种肝细胞核因子4α（HNF4-α）拮抗剂及其用途。本发明选择的HNF4-α拮抗剂被确认能够特异性结合到HNF4-α的配体结合域，从而抑制HNF4-α的活性。与传统已知的HNF4-α拮抗剂相比，本发明的HNF4-α拮抗剂可以显著特异性地降低Wnt5a的表达，并且还能抑制胃癌细胞的生长。因此，本发明的HNF4-α拮抗剂不仅可以用作预防和治疗癌症的药物组合物或健康功能性食品，还可以应用于治疗或预防由于HNF4-α过度表达而导致的疾病的组合物。
• 1,1'-Diadamantyl carboxylic acids, medicaments containing such compounds and their use
  申请人：Eckhardt Matthias

  公开号：US20110269736A1

  公开（公告）日：2011-11-03

  The present invention relates to compounds defined by formula (I) wherein the group R is defined as in claim 1 , possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases.

  本发明涉及具有有价值的药理活性的公式（I）所定义的化合物，其中R基团如权利要求1所定义。特别地，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以通过抑制该酶而受到影响的疾病，例如代谢性疾病。
• US8309597B2
  申请人：——

  公开号：US8309597B2

  公开（公告）日：2012-11-13
• US9795586B2
  申请人：——

  公开号：US9795586B2

  公开（公告）日：2017-10-24
• [EN] 1,1'-DIADAMANTYL CARBOXYLIC ACIDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE<br/>[FR] ACIDES 1,1'-DIADAMANTYL CARBOXYLIQUES, MÉDICAMENTS CONTENANT DE TELS COMPOSÉS ET APPLICATION ASSOCIÉE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010010174A1

  公开（公告）日：2010-01-28

  The present invention relates to compounds defined by formula (I) wherein the group R is defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases.

  本发明涉及由式（I）定义的化合物，其中基团R如权利要求1中所定义，具有有价值的药理活性。特别是这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，如代谢性疾病。